Study wrapper · #1227
Review Article: Fibrosis Reversal in Metabolic Dysfunction-Associated Steatohepatitis-The Promise of Emerging Therapeutics.
Editor's note
A narrative review rather than a pooled analysis, so the numbers are drawn from individual trials and not statistically combined. Its most useful line for peptide readers is the caveat the authors put on their own optimism: the link between histological improvement and reduced long-term clinical events remains unproven. Worth carrying as landscape context for where semaglutide now sits in liver-disease management, not as new efficacy evidence.
Plain-language abstract
This narrative review maps the drug landscape for metabolic dysfunction-associated steatohepatitis, focusing on whether therapies can improve liver scarring. It reports that semaglutide produced at least one stage of fibrosis improvement in 37% of patients versus 22% on placebo at 72 weeks, alongside resmetirom's 26% versus 14% at 52 weeks. Incretin-based agents, FGF21 analogues, and combination regimens make up much of the pipeline.